CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer
- Written by PR Newswire
 |
SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche's PD-L1 checkpoint inhibitor, along with...
